Renaissance Technologies’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Renaissance Technologies’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.35M	Buy	+68,077	New	+$3.53M	0.01%	1536
2023 Q3	–	Sell	-84,447	Closed	-$1.19M	–	3904
2023 Q2	$1.19M	Sell	84,447 -53,733	-39%	-$719K	﹤0.01%	2364
2023 Q1	$1.49M	Buy	138,180 +71,480	+107%	+$942K	﹤0.01%	2212
2022 Q4	$999K	Sell	66,700 -55,100	-45%	-$802K	﹤0.01%	2531
2022 Q3	$1.56M	Buy	121,800 +67,800	+126%	+$772K	﹤0.01%	2197
2022 Q2	$523K	Sell	54,000 -104,700	-66%	-$977K	﹤0.01%	3140
2022 Q1	$1.58M	Sell	158,700 -144,600	-48%	-$1.53M	﹤0.01%	2414
2021 Q4	$3.57M	Buy	+303,300	New	+$3.73M	﹤0.01%	1745
2021 Q1	–	Sell	-16,700	Closed	-$295K	–	3525
2020 Q4	$295K	Buy	16,700 +1,000	+6%	+$17.6K	﹤0.01%	3041
2020 Q3	$241K	Buy	+15,700	New	+$295K	﹤0.01%	3064

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Renaissance Technologies's KNSA Position: Q2 2026 in Review

Renaissance Technologies opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 68,077 shares worth $4.35M. The stake represents 0.01% of the portfolio and ranks #1536 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in KNSA as recently as Q2 2023.

Renaissance Technologies first reported a position in KNSA in Q3 2020 and has held it in 10 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Renaissance Technologies held 68,077 shares of Kiniksa Pharmaceuticals worth $4.35M as of Q2 2026.
Kiniksa Pharmaceuticals was a new Renaissance Technologies position in Q2 2026.
Kiniksa Pharmaceuticals made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1536 holding.
Renaissance Technologies first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and has held it in 10 quarters since.
267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.